Cel Sci Corporation (CVM)

[trickledownfacists]

Global Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Pipeline Review, H2 2015 - 9 Companies & 21 Drug Profiles

Companies Involved in Therapeutics Development

CEL-SCI Corporation

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zfq4lg/severe_acute) has announced the addition of the "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Kineta, Inc.
Myelo Therapeutics GmbH
Nanotherapeutics, Inc.
Novavax, Inc.
Phelix Therapeutics, LLC
Protein Sciences Corporation
Drug Profiles

CEL-1000
D-3252
Drugs to Inhibit Cathepsin L for Infectious Diseases
FDX-000
IKT-014
LCA-60
ML-188
MMCatLMC
Monoclonal Antibody for SARS Virus Infections
Myelo-001
rOAS
SARS vaccine
SARS vaccine
SARS-CoV Vaccine
severe acute respiratory syndrome vaccine
severe acute respiratory syndrome vaccine + middle east respiratory syndrome vaccine
Small Molecule for SARS
Small Molecule to Inhibit Cathepsin L for SARS and Ebola Viral Infections
SSYA-10001
Synthetic Peptide to Target Spike Protein for SARS Infection